Skip to main content

Integrative Medicine

RSS  

Articles

  • Clinical Briefs With Comments from Russell H. Greenfield, MD

    Pycky, Pycky — French Maritime Bark and Menopause, Anxious Hearts — Anxiety and CVD
  • Full January 1, 2008 Issue in PDF

  • Hawthorn: An Herb that Helps Hypertension

    An integrative approach to high blood pressure ventures into many realms, including herbal medicine. For supporting cardiovascular health and treating heart disease, hawthorn is a botanical treatment that often comes to mind.
  • Ginkgo biloba and Dementia

    The term "dementia" refers to central nervous system (CNS) pathology that makes it hard for a person to remember, learn, and communicate. It may also involve perception, emotional behavior, and cognitive skills. Usually, dementia presents as forgetfulness, but may eventually lead to disruptive behavior.
  • Supplement: Patient Handout: The Common Hawthorn

  • 'Tis the Season

    Neither antibiotics nor nasal steroids nor the combination of the two reduces the duration of acute sinusitis symptoms compared with placebo.
  • Intravenous Bisphosphonate and Facial Bones

    IV bisphosphonate treatment is associated with an increased risk of inflammation in the bones of the jaw and face.
  • Diagnosing Early Pancreatic Cancer

    Although pancreatic cancer growth is considered rapid, early recognition of resectable disease remains the best chance for long-term survival. It is possible that an early sign of evolving pancreatic neoplasm is glucose intolerance. In a series of 30 pancreatic cancer patients evaluated at the Mayo Clinic, CT scans obtained 6 months or more before the diagnosis revealed potentially resectable lesions in some, and this was notably true for those who had CT scans and new-onset diabetes several months before the diagnosis of pancreatic cancer. Thus, physicians evaluating adults with newly diagnosed diabetes should consider the possibility that the glucose intolerance is an accompaniment of early pancreatic neoplasia.
  • Sorafenib Tablets(Nexavar®)

    Sorafenib has been approved by the FDA forthe treatment of inoperable hepatocellular cancer. It is an oral multikinase inhibitor that was previously approved for advanced renal cell carcinoma. It is manufactured by Bayer HealthCare AG in Germany and marketed by Bayer Pharmaceuticals Corporation as Nexavar.
  • Clinical Briefs by Louis Kuritzky, MD

    Incidentalomas:It's All In Your Head, Skin Cancer Screening: Our Patients Want It!, and Bell's Palsy: Steroids, Acyclovir, Both, or Neither?